⚠ Evidence note: Most trends in this area rest on anecdote and mechanism; where real evidence exists it is usually for narrower claims than the trend makes.
Myostatin Inhibitors in Longevity Practice
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-11-11 — Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial.: COURAGE phase 2 double-blind placebo-controlled RCT (reported n=975) [human-rct] provides human proof of concept for trevogrumab-mediated lean-mass preservation during semaglutide-induced weight loss in adults with obesity, but the trevogrumab–garetosmab combination caused unacceptable adverse events despite greater body-composition improvements, and neither functional nor anti-aging benefit is established by the supplied finding. [human-rct] (novelty: 4)
- 2026-10-03 — Myostatin inhibitors and the paradox of larger but weaker muscles: Attia (podcast/expert commentary, no new trial data) frames the class-wide paradox that myostatin-pathway drugs — old and new — reliably enlarge lean mass but repeatedly fail to translate into measurable strength gains in clinical readouts. [expert-opinion] (novelty: 3)
Open questions
Related
Contributing findings
Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial.
11-nov-2026
novelty 4
per-area 4
strengthens
Myostatin inhibitors and the paradox of larger but weaker muscles
03-oct-2026
novelty 3
per-area 3
strengthens